Drug Repurposing, also known as drug repositioning or reprofiling, is a strategy in pharmaceutical research that involves identifying new uses for existing drugs beyond their originally intended therapeutic areas. This approach capitalizes on the extensive safety and pharmacological data available for approved or investigational drugs, aiming to expedite the development of treatments for various medical conditions. The process of drug repurposing involves systematic screenings, bioinformatics analyses, and preclinical and clinical repurposing evaluations to uncover novel therapeutic applications. By exploring new indications for established drugs, researchers can potentially bypass some of the lengthy and costly phases of drug development, accelerating the availability of treatments. One notable example of successful drug repurposing is the use of minoxidil, initially developed for hypertension, which was later found to be effective in treating male pattern baldness. This strategy has gained momentum in recent years as a cost-effective and time-efficient means of addressing unmet medical needs and expanding treatment options across diverse disease areas.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia